Saturday, May 31, 2008

Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate

Giant Cell Tumor is a Rare Bone Tumor Afflicting Younger Adults For Which Few Treatment Options Exist

CHICAGO – May 31, 2008 – Amgen (NASDAQ:AMGN) today announced interim results of an open-label Phase 2 study demonstrating a positive response rate to administration of denosumab in subjects with recurrent or unresectable giant cell tumor of bone. The study was presented at the 2008 American Society of Clinical Oncology (ASCO) annual meeting.

Read the rest of this entry

Posted in Press Releases, Pipeline News

Thursday, May 29, 2008

Amgen to Webcast Investor Meeting at Upcoming American Society of Clinical Oncology Conference

THOUSAND OAKS, Calif. – May 29, 2008 – Amgen (NASDAQ:AMGN) will webcast its investor meeting at the upcoming American Society of Clinical Oncology (ASCO) Conference on Sunday, June 1 at 8 p.m. Central Time. Members of Amgen’s scientific and management team will participate at the meeting. The company plans to highlight key compounds in its pipeline, including denosumab.

Read the rest of this entry

Posted in Press Releases

Wednesday, May 28, 2008

Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial Versus Weekly Alendronate (FOSAMAX(R))

Phase 3 Study Showed Bone Mineral Density Gains at All Skeletal Sites Measured with Denosumab Administration

BARCELONA, Spain – May 28, 2008 – Amgen (NASDAQ: AMGN) today announced complete results from a head-to-head, double-blind study comparing the effects of twice-yearly subcutaneous injections of denosumab versus weekly oral doses of alendronate (FOSAMAX(R)) on bone mineral density (BMD) in postmenopausal women with low BMD. The results were presented during a late breaking session at this year’s 35th Annual European Symposium on Calcified Tissues (ECTS) meeting. Top-line results of this study were previously reported in January 2008.

Read the rest of this entry

Posted in Press Releases, Pipeline News

Tuesday, May 27, 2008

Amgen Announces Webcast to Discuss Results of denosumab Phase 3 Head-to-Head Study versus alendronate at the Upcoming European Symposium on Calcified Tissues Conference

THOUSAND OAKS, Calif. – May 27, 2008 – Amgen (NASDAQ:AMGN) today announced that it will hold a conference call on Wednesday, May 28, 2008, beginning at 8 a.m. Eastern Time to discuss the results of the denosumab Phase 3 head-to-head study versus alendronate (the "141" study) at the upcoming European Symposium on Calcified Tissues (ECTS) Conference in Barcelona, Spain. Speakers will include the principal study investigator, Jacques P. Brown, M.D., Head, Division of Rheumatology, Le Centre hospitalier universitaire de Quebec, and Catherine Stehman-Breen, M.D., Amgen’s vice president, Global Development - Bone Therapeutic Area.

Read the rest of this entry

Posted in Press Releases

Thursday, May 22, 2008

Amgen Posts Medical Education and Foundation Grants and Donations as Part of the Company's 'Clearly Amgen' Initiative

THOUSAND OAKS, Calif. – May 22, 2008 – Amgen (NASDAQ: AMGN) today posted to the company’s Web site grants and donations made by the Amgen Medical Education department (AmgenMED) and the Amgen Foundation. The posting is the latest element of Clearly Amgen, a section of the Company’s Web site designed to provide clear and easy access to Amgen’s policies and practices. Grants, donations and charitable contributions will be updated quarterly along with a brief description of each program or project.

Read the rest of this entry

Posted in Press Releases